NCT02098616 (RHACE 1) is a NA clinical trial of DCV/ASV/BMS-791325 in Hepatitis C, sponsored by Timothy Morgan, MD.

Who is sponsoring NCT02098616?

NCT02098616 is sponsored by Timothy Morgan, MD.

What drugs are being tested in NCT02098616?

Interventions in NCT02098616: DCV/ASV/BMS-791325, DCV/ASV/BMS-791325 + RBV.

What condition does NCT02098616 study?

NCT02098616 studies Hepatitis C.

Is NCT02098616 still recruiting?

NCT02098616 is currently completed. Last updated 15 April 2016.

Last reviewed 2016-04-15 · How we verify

NCT02098616: RHACE 1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RHACE 1: Rapid HepAtitis C Elimination Trial - A Pilot Evaluation of Twice Daily Fixed Dose Combination Asunaprevir +Daclatasvir + BMS-791325 ± Weight Based Ribavirin in Treatment-Naïve, Non-cirrhotic Patients With Chronic Genotype 1a Hepatitis-C for Eight, Six or Four Weeks

Completed NA Last updated 15 April 2016

What this trial tests

NA trial testing DCV/ASV/BMS-791325 in Hepatitis C in 25 participants. Completed in 1 February 2016.

Timeline

1 July 2014

Primary endpoint
1 February 2016

1 February 2016

Quick facts

Lead sponsor	Timothy Morgan, MD
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	1 July 2014
Primary completion	1 February 2016
Estimated completion	1 February 2016
Sites	1 location across United States

Drugs / interventions tested

DCV/ASV/BMS-791325 — full drug profile →
DCV/ASV/BMS-791325 + RBV — full drug profile →

Conditions studied

Hepatitis C — all drugs for Hepatitis C →

Sponsor

Timothy Morgan, MD — full company profile →

Who can join

18 and older, any sex, with Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sustained Virologic Response
Time frame: Post treatment week 12
Proportion of treated subjects in each enrolled arm with sustained virologic response (SVR)12. SVR12 is defined as HCV RNA \< lower limit of quantification (LLOQ) target detected or target not detected (TD/TND) at post treatment Week 12

Sponsor's own description

The purpose of this study is to determine whether treatment with Daclatasvir/Asunaprevir/BMS-791325, with or without ribavirin, for 8, 6, or 4 weeks is feasible for the treatment of genotype 1a chronic hepatitis C in patients without cirrhosis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The New Era of Interferon-Free Treatment of Chronic Hepatitis C.
Solbach P, Wedemeyer H. · · 2015 · cited 18× · PMID 26557839 · DOI 10.1159/000433594

Verify or expand the search:

Other trials of DCV/ASV/BMS-791325

Trials testing the same drug.

NCT02175966 — Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Ch · Phase 2 · completed
NCT02170727 — A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis · Phase 3 · completed

Other recruiting trials for Hepatitis C

Currently open trials in the same condition.

NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
NCT05208697 — Tele-Harm Reduction · NA · active not recruiting

Other Timothy Morgan, MD trials

Trials by the same sponsor.

NCT02776059 — Pegfilgrastim in Patients With Alcoholic Hepatitis · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02098616 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Timothy Morgan, MD
Last refreshed: 15 April 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02098616.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing